SYRE
Spyre Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -7.1% ·
share flow -1.7% ·
net new positions -7.7%
· formula
Broad distribution: falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | +2 | 602.45K | $53.61M | +2 | n/a |
| Q2 2026 | 99 | +22 | 55.44M | $4.93B | +25 | −3 |
| Q1 2026 | 80 | +10 | 41.69M | $2.10B | +12 | −2 |
| Q4 2025 | 69 | +2 | 41.90M | $1.37B | +2 | n/a |
| Q3 2025 | 13 | -1 | 23.21M | $388.94M | +1 | −2 |
| Q2 2025 | 11 | 0 | 22.40M | $335.38M | +2 | −2 |
| Q1 2025 | 8 | -2 | 6.01M | $96.96M | n/a | −2 |
| Q4 2024 | 10 | +1 | 7.67M | $178.64M | +2 | −1 |
| Q3 2024 | 8 | 0 | 4.78M | $140.58M | +1 | −1 |
| Q2 2024 | 8 | n/a | 3.96M | $93.00M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 9.06M | +0.1% | $151.85M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 2 | BlackRock ✦ (passive) | 3.98M | -0.6% | $66.75M | 0.0% | ▼ Trim | 2 | SEC ↗ ×11 |
| 3 | The Vanguard Group ✦ (passive) | 3.05M | -0.5% | $51.13M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 4 | State Street Global Advisors ✦ (passive) | 1.79M | +11.9% | $29.92M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 5 | Wellington Management ✦ | 1.64M | +8.4% | $27.49M | 0.0% | ▲ Add | 6 | SEC ↗ ×5 |
| 6 | Geode Capital Management ✦ (passive) | 1.23M | -0.2% | $20.54M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 7 | T. Rowe Price ✦ | 620.62K | -33.3% | $10.40M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 8 | JPMorgan Chase ✦ | 551.97K | n/a | $9.25M | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 9 | Millennium Management ✦ | 408.20K | New | $6.84M | 0.0% | New | 1 | SEC ↗ |
| 10 | Morgan Stanley ✦ | 334.72K | n/a | $5.61M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 11 | Goldman Sachs Group ✦ | 329.53K | n/a | $5.52M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 12 | Capital World Investors ✦ | 200.17K | -42.9% | $3.35M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 17.05K | -5.2% | $285,709 | 0.0% | ▼ Trim | 2 | SEC ↗ ×4 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Millennium Management | $6.84M | 0.0% |
Exited
| Adage Capital Partners | $9.13M | was 0.0% |
| Renaissance Technologies | $463,112 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 197 holders, 82.12M shares, $4.06B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 229 sh · $21,428
Officer · 1.50K sh · $135,405
Officer · 3.07K sh · $285,449
Officer · 600 sh · $53,442
Officer · 2.10K sh · $193,032
Officer · 17.50K sh · $1.57M
Officer · 18.23K sh · $1.63M
Officer · 400 sh · $36,000
Officer · 16.55K sh · $1.44M
Officer · 900 sh · $77,625
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
9.2% of class · View original SEC filing ↗
9.2% of class · View original SEC filing ↗